[HTML][HTML] RNA therapeutics: updates and future potential
C Zhang, B Zhang - Science China Life Sciences, 2023 - Springer
Recent advancements in the production, modification, and cellular delivery of RNA
molecules facilitated the expansion of RNA-based therapeutics. The increasing …
molecules facilitated the expansion of RNA-based therapeutics. The increasing …
Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics
Cancer, infectious diseases, and metabolic and hereditary genetic disorders are a global
health burden affecting millions of people, with contemporary treatments offering limited …
health burden affecting millions of people, with contemporary treatments offering limited …
[HTML][HTML] Tailoring combinatorial lipid nanoparticles for intracellular delivery of nucleic acids, proteins, and drugs
Lipid nanoparticle (LNP)-based drug delivery systems have become the most clinically
advanced non-viral delivery technology. LNPs can encapsulate and deliver a wide variety of …
advanced non-viral delivery technology. LNPs can encapsulate and deliver a wide variety of …
RNA therapeutics in the clinic
A Curreri, D Sankholkar, S Mitragotri… - Bioengineering & …, 2023 - Wiley Online Library
Ribonucleic acid (RNA) therapeutics are being actively researched as a therapeutic
modality in preclinical and clinical studies. They have become one of the most ubiquitously …
modality in preclinical and clinical studies. They have become one of the most ubiquitously …
Albumin-hitchhiking: fostering the pharmacokinetics and anticancer therapeutics
Nanotherapeutics demonstrate poor accumulation in the tumor microenvironment due to
poor extravasation and penetration into the tumor. Therapeutics such as oligonucleotides …
poor extravasation and penetration into the tumor. Therapeutics such as oligonucleotides …
[HTML][HTML] The sense of antisense therapies in ALS
SH Van Daele, P Masrori, P Van Damme… - Trends in Molecular …, 2024 - cell.com
Abstract Treatment of patients with amyotrophic lateral sclerosis (ALS) has entered a new
era now that encouraging results about antisense oligonucleotides (ASOs) are becoming …
era now that encouraging results about antisense oligonucleotides (ASOs) are becoming …
Therapeutic RNA-silencing oligonucleotides in metabolic diseases
Recent years have seen unprecedented activity in the development of RNA-silencing
oligonucleotide therapeutics for metabolic diseases. Improved oligonucleotide design and …
oligonucleotide therapeutics for metabolic diseases. Improved oligonucleotide design and …
[HTML][HTML] Recent advances and prospects for lipid-based nanoparticles as drug carriers in the treatment of human retinal diseases
The delivery of cures for retinal diseases remains problematic. There are four main
challenges: passing through multiple barriers of the eye, the delivery to particular retinal cell …
challenges: passing through multiple barriers of the eye, the delivery to particular retinal cell …
Identifying an optimal neuroinflammation treatment using a nanoligomer discovery engine
Acute activation of innate immune response in the brain, or neuroinflammation, protects this
vital organ from a range of external pathogens and promotes healing after traumatic brain …
vital organ from a range of external pathogens and promotes healing after traumatic brain …
The landscape of nanoparticle-based siRNA delivery and therapeutic development
Five small interfering RNA (siRNA)-based therapeutics have been approved by the Food
and Drug Administration (FDA), namely patisiran, givosiran, lumasiran, inclisiran, and …
and Drug Administration (FDA), namely patisiran, givosiran, lumasiran, inclisiran, and …